Lion TCR is a clinical-stage biotech developing engineered T-cell immunotherapy against viral-related cancers and chronic hepatitis B. Its lead candidate, LioCyx™, is a personalized HBV-specific TCR T-cell therapy targeting hepatocellular carcinoma (HCC). The company intends to use the Series A proceeds to advance ongoing clinical trials of LioCyx™ in major hospitals in China and Singapore. It also plans to broaden its product pipeline to address other viral-related solid tumours and to pursue clearance of chronic hepatitis B. Lion TCR operates manufacturing and clinical trial operations in China and Singapore and licenses engineered T-cell technologies from A*STAR (Prof. Antonio Bertoletti’s lab) and the Technical University of Munich (Prof. Urlike Protzer’s lab). The company is led by founder and CEO Dr. Victor Li and scientific founder Prof. Antonio Bertoletti.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

May 2018